Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment.
Abstract
Raynaud's phenomenon (RP) is a condition characterized by episodic, excessive vasoconstriction in the fingers and toes, triggered by cold or stress. This leads to a distinctive sequence of color changes in the digits. Pallor indicates reduced blood flow due to oxygen deprivation, while erythema appears as reperfusion. RP can be primary, with no identifiable underlying cause, or secondary, associated with other conditions. These conditions include autoimmune diseases, most commonly systemic sclerosis, vascular diseases; and neurological conditions. While the exact cause of RP remains unclear, genetic and hormonal (estrogen) factors are likely contributors. The pathogenesis of RP involves a complex interaction between the vascular wall, nerves, hormones, and humoral factors, disrupting the balance between vasoconstriction and vasodilation. In primary RP, the vascular abnormalities are primarily functional. However, in secondary RP, both functional and structural components occur in blood vessels. This explains why digital tissue damage frequently occurs in secondary RP but not primary RP. Diagnosis of RP is primarily clinical. Recent advancements in imaging techniques have aided in diagnosis and monitoring, but nail fold capillaroscopy remains the gold standard for distinguishing between primary and secondary RP. If there are signs of acute ischemic injury, vascular imaging, particularly preoperatively, is crucial to rule out other vaso-occlusive conditions. Management of RP focuses on alleviating symptoms and preventing tissue damage. Vasodilator medications are the first-line treatment when general measures like warmth and stress management are not sufficient. Dihydropyridine calcium channel blockers (CCBs), such as nifedipine, are commonly used for vasodilation. Phosphodiesterase-5 inhibitors and prostaglandin analogs are alternative options for patients who do not respond to CCBs or have ischemic tissue damage. Bosentan, an endothelin-1 receptor antagonist, has shown effectiveness in treating and preventing digital ulcers, especially in patients with multiple ulcers. For severe cases, botulinum toxin injections or sympathectomy surgery can be used to control RP symptoms. However, botulinum toxin injections require repeated administration, and sympathectomy's long-term effectiveness is uncertain. Fat grafting is a promising surgical therapy for promoting healing and preventing tissue injury.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 해부 | blood
|
scispacy | 1 | ||
| 해부 | nerves
|
scispacy | 1 | ||
| 해부 | tissue
|
scispacy | 1 | ||
| 해부 | Fat
|
scispacy | 1 | ||
| 합병증 | digits
|
scispacy | 1 | ||
| 합병증 | erythema
|
scispacy | 1 | ||
| 합병증 | nail
|
scispacy | 1 | ||
| 합병증 | ulcers
|
scispacy | 1 | ||
| 약물 | oxygen
|
C0030054
oxygen
|
scispacy | 1 | |
| 약물 | estrogen
|
C0014939
estrogens
|
scispacy | 1 | |
| 약물 | calcium
|
C0006675
calcium
|
scispacy | 1 | |
| 약물 | CCBs
→ calcium channel blockers
|
C0006684
Calcium Channel Blockers
|
scispacy | 1 | |
| 약물 | nifedipine
|
C0028066
nifedipine
|
scispacy | 1 | |
| 약물 | Phosphodiesterase-5
|
C0757672
Cyclic Nucleotide Phosphodiesterases, Type 5
|
scispacy | 1 | |
| 약물 | prostaglandin analogs
|
C0033568
Prostaglandins, Synthetic
|
scispacy | 1 | |
| 약물 | Bosentan
|
C0252643
bosentan
|
scispacy | 1 | |
| 약물 | Dihydropyridine calcium
|
scispacy | 1 | ||
| 약물 | prostaglandin
|
scispacy | 1 | ||
| 질환 | Raynaud
|
C0034734
Raynaud Disease
|
scispacy | 1 | |
| 질환 | Raynaud's phenomenon
|
C0034735
Raynaud Phenomenon
|
scispacy | 1 | |
| 질환 | Pallor indicates reduced blood flow
|
scispacy | 1 | ||
| 질환 | erythema
|
C0041834
Erythema
|
scispacy | 1 | |
| 질환 | autoimmune diseases
|
C0004364
Autoimmune Diseases
|
scispacy | 1 | |
| 질환 | systemic sclerosis
|
C0036421
Systemic Scleroderma
|
scispacy | 1 | |
| 질환 | vascular diseases
|
C0042373
Vascular Diseases
|
scispacy | 1 | |
| 질환 | vascular abnormalities
|
C0241657
Abnormality of the vasculature
|
scispacy | 1 | |
| 질환 | tissue damage
|
C0010957
Tissue damage
|
scispacy | 1 | |
| 질환 | acute ischemic injury
|
scispacy | 1 | ||
| 질환 | ulcers
|
C0041582
Ulcer
|
scispacy | 1 | |
| 질환 | RP symptoms
|
C1457887
Symptoms
|
scispacy | 1 | |
| 기타 | vascular
|
scispacy | 1 | ||
| 기타 | vascular wall
|
scispacy | 1 | ||
| 기타 | blood vessels
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | endothelin-1
|
scispacy | 1 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.